Carvykti Европска Унија - Румунски - EMA (European Medicines Agency)

carvykti

janssen-cilag international nv - ciltacabtagene autoleucel - mielom multiplu - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Tecvayli Европска Унија - Румунски - EMA (European Medicines Agency)

tecvayli

janssen-cilag international n.v. - teclistamab - mielom multiplu - agenți antineoplazici - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Sugammadex Amomed Европска Унија - Румунски - EMA (European Medicines Agency)

sugammadex amomed

aop orphan pharmaceuticals gmbh - sugammadex sodium - blocaj blocant - toate celelalte produse terapeutice - inversarea blocadei neuromusculare indusă de rocuroniu sau vecuroniu. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

OXIGEN LINDE 100% Румунија - Румунски - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

oxigen linde 100%

linde gaz romania s.r.l. - romania - oxigenum - gaz medicinal criogenic - 100% - alte preparate terapeutice gaze medicinale

Akeega Европска Унија - Румунски - EMA (European Medicines Agency)

akeega

janssen-cilag international n.v. - abiraterone acetate, niraparib tosilate monohydrate - neoplasmele prostatice, rezistent la castrare - agenți antineoplazici - treatment of adult patients with prostate cancer.

Bekemv Европска Унија - Румунски - EMA (European Medicines Agency)

bekemv

amgen technology (ireland) uc - eculizumab - hemoglobinurie, paroxismal - imunosupresoare - bekemv is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). dovezi de beneficii clinice este demonstrată la pacienții cu hemoliză cu simptom clinic(s) indică un grad înalt de activitate a bolii, indiferent de transfuzie istorie (a se vedea secțiunea 5.

Talvey Европска Унија - Румунски - EMA (European Medicines Agency)

talvey

janssen-cilag international n.v. - talquetamab - mielom multiplu - agenți antineoplazici - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.